Navigation Links
AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment

QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract outlining first in vitro data on its pyridopyrazine derivatives with high selectivity for PI3K inhibition, at the American Association for Cancer Research (AACR) Annual Meeting being held this week at the Los Angeles Convention Center in Los Angeles, California.

Results

The poster #2379 entitled, "New Generation of Anilino-Substituted Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-Inhibition", reviewed for the first time, results for a preclinical development program on a new generation of pyridopyrazine derivatives which clearly indicate that these drug candidates selectively inhibit PI3K.

Furthermore, an optimization process of our already known aryl-pyridopyrazine series led to the identification of a new lead compound in this series. A medicinal chemistry program was then initiated which resulted in the synthesis of new anilino-substituted pyridopyrazines. Out of this second generation series, several derivatives also with highly-selective PI3K inhibition as well as improved cellular efficacy and better drug-like properties, were identified.

    Conclusions


         - Novel low molecular weight kinase inhibitor

         - Excellent in vitro activity against PI3K

         - High selectivity against a panel of more than 50 kinases

         - Anti-proliferative efficacy in diverse tumor cell-lines

         - Promising bioavailability observed for lead compound

         - PI3K signalling network covers enormous therapeutic potential

"We are pleased with these results which exemplify our capability of developing novel the rapeutic approaches that add to the breadth and depth of our product pipeline," said Dr Jurgen Engel, Executive Vice President, Global R&D and Chief Operating Officer at AEterna Zentaris. "The potential for cancer treatment with agents inhibiting the PI3K pathway has become a focus in recent drug discovery and development research. We believe that by developing novel selective PI3K inhibiting small molecular compounds, we are positioning ourselves as one of the leaders in this promising therapeutic approach."

Cellular substrate phosphorylation studies targeting the inhibition of PI3K and functional cellular assays of tumor cell proliferation have been performed. In addition, physicochemical and initial ADMET data were collected. Several derivatives are currently undergoing first pharmacokinetic in vivo studies.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at www.aeternazentaris.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual res ults to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.at www.aeternazentaris.com.

CONTACT: Jenene Thomas, Senior Director, Investor Relations & CorporateCommunications, (418) 655-6420, ; PaulBurroughs, Media Relations, (418) 652-8525, ext. 406, jenene.thomas@aeternazentaris.com paul.burroughs@aeternazentaris.com

Ticker Symbol: (Toronto:AEZ.),(NASDAQ-NMS:AEZS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
11. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 Brain Cancer patients ... method at West Cancer Center . Optune™, ... to inhibit cancer cell replication causing death of cancer ... a decade to show a significant extension in overall ... patients. Currently, West Cancer Center is the only medical ...
(Date:2/11/2016)... , Feb. 11, 2016  AbbVie, a ... AbbVie Rheumatology Scholarship, designed to provide financial support ... as they pursue higher education goals. Fifteen scholars ... the 2016-2017 school year. The AbbVie Rheumatology Scholarship ... Haas , vice president, corporate social responsibility, brand ...
(Date:2/11/2016)... -- PLAD, Inc. (OTC Pink: PLAD) is pleased to announce that ... targets, are adding key personnel to their national sales ... States Patent and Trademark Office for the characters "P.L.A.D.".    ... PLAD, Inc.  In January, PLAD established their presence in ... two new customers, Cumberland Goodwill EMS and Meadville Ambulance, ...
Breaking Medicine Technology:
(Date:2/11/2016)... Kimberton, PA (PRWEB) , ... February 12, 2016 , ... ... Carolyn’s classes are a fun and exciting way to get fit and healthy. Located ... Training LLC announces dates for a class designed for horseback riders who want to ...
(Date:2/11/2016)... ... February 11, 2016 , ... Student-doctors ... Osteopathic Association’s (AOA) Match Program Tuesday, February 9, taking one of the final ... osteopathic graduate medical education positions across the country. Of the 103 student-doctors who ...
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of Pain Research has ... The SJR uses data taken from the Scopus database (Elsevier B.V.) and is a ... received by the journal over a three year period and also the importance of ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative Health and ... for their simultaneous grand openings in March. All seven practices are set to ... wondering, is reversing diabetes possible? According to this 2011 CNN article it is ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for Plans and Purchasers.” Executives ... system that’s partnering with Intel on value-based health benefits program Connected Care, will ...
Breaking Medicine News(10 mins):